1,995
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Further implications on the global real-world vaccine effectiveness against SARS-CoV-2

, , , , , , ORCID Icon, , , , , , , , , , ORCID Icon, ORCID Icon & show all
Pages 1355-1357 | Received 25 Jul 2022, Accepted 02 Aug 2022, Published online: 18 Aug 2022

References

  • Chuenkitmongkol S, Solante R, Burhan E, et al. Expert review on global real-world vaccine effectiveness against SARS-CoV-2 Expert Review of Vaccines. [cited 2022 Jun 30]. 2022. Available from: https://doi.org/10.1080/14760584.2022.2092472 DOI: 10.1080/14760584.2022.2092472
  • Chariyalertsak S, Intawong, K., Chalom, K, et al. Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand. Research Square 2022. Preprint. [cited 2022 Jul]. Preprint https://doi.org/10.21203/rs.3.rs-1792139/v1
  • Palacios R, Batista, A.P., Albuquerque, C.S.N, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil. The PROFISCOV Study. [cited 2022 Jul]. Available from: https://ssrn.com/abstract=3822780
  • Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
  • Polack FP, Thomas, S.J., Kitchin, N., et al. C4591001 clinical trial group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
  • Mayr FB, Talisa VB, Shaikh O, et al. effectiveness of homologous or heterologous Covid-19 boosters in veterans. N Engl J Med. 2022;386(14):1375–1377.
  • Accorsi EK, Britton A, Shang N, et al. Effectiveness of homologous and heterologous Covid-19 boosters against omicron. N Engl J Med. 2022 Jul;386(25):2433–2435.
  • Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–592.
  • Intawong K, Olson D, Chariyalertsak S, et al. Application technology to fight the COVID-19 pandemic: lessons learned in Thailand. Biochem Biophys Res Commun. 2021 January 1st;534:830–836.
  • Tuekprakhon, Huo J, Nutalai R, et al. 200 bioRxiv preprint. DOI:10.1101/2022.05.21.492554
  • Regev‑Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–1380.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.